FoscarnetSodium , 97% , 63585-09-1

Synonym(s):
Foscarnet;Foscarnet sodium hexahydrate;Phosphonoformic acid trisodium salt hexahydrate;Sodium phosphonoformate tribasic hexahydrate

CAS NO.：63585-09-1

Empirical Formula: CNa3O5P

Molecular Weight: 191.95

MDL number: MFCD00013973

EINECS: 695-653-7

PRODUCT Properties

• Melting point: >250°
• storage temp.: Inert atmosphere,Room Temperature
• form: Solid
• color: White to off-white
• Water Solubility: ≥ 24.9mg/mL in water
• CAS DataBase Reference: 63585-09-1(CAS DataBase Reference)

Description and Uses

Foscamet sodium is a new, injectable antiviral agent useful in the treatment of severe cytomegalovirus retinitis in immunodepressed patients. Foscarnet sodium acts by inhibiting viral-specific DNA polymerases; its side-effects include decreased hemoglobin levels and acute tubular necrosis.

Inhibits viral DNA polymerase and reverse transcriptase.
Foscarnet is the only antiviral approved by the FDA for the treatment of acyclovir-resistant HSV infections, a growing problem in the AIDS population. Foscarnet does not require HSV-encoded thymidine kinase. Foscarnet therapy reduces the healing time, pain, and viral shedding. It is administered intravenously, 40 mg/kg every 8 to 12 hours within 7 to 10 days in patients suspected of having acyclovir-resistant herpes simplex infection. Foscarnet is administered for 10 days. Associated side effects include azotemia secondary to nephrotoxicity, hyperphosphatemia, hypocalcemia, anemia, nausea, vomiting, and genital ulceration. Patients may eventually develop resistant strains. Preliminary trials indicate that topical 1%foscarnet cream may have some benefit for the treatment of acyclovir-resistant mucocutaneous HSV infection in patients with AIDS.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H319
• Precautionary statements: P305+P351+P338
• Toxicity: LD50 i.p. in mice: 2000-4000 mmol/kg (Eriksson)